Comparison of neoadjuvant treatment and surgery first for resectable or borderline resectable pancreatic carcinoma: A systematic review and network meta-analysis of randomized controlled trials.
<h4>Background</h4>Current treatment recommendations for resectable or borderline pancreatic carcinoma support upfront surgery and adjuvant therapy. However, neoadjuvant therapy (NT) seems to increase prognosis of pancreatic carcinoma and come to everyone's attention gradually. Rand...
Main Authors: | Lu Huan, Fucai Yu, Ding Cao, Hantao Zhou, Maoling Qin, Yang Cao |
---|---|
Format: | Article |
Language: | English |
Published: |
Public Library of Science (PLoS)
2024-01-01
|
Series: | PLoS ONE |
Online Access: | https://journals.plos.org/plosone/article/file?id=10.1371/journal.pone.0295983&type=printable |
Similar Items
-
Neoadjuvant Therapy for Resectable and Borderline Resectable Pancreatic Cancer: A Meta-Analysis of Randomized Controlled Trials
by: Jordan M. Cloyd, et al.
Published: (2020-04-01) -
Editorial: Neoadjuvant treatment for resectable and borderline resectable pancreatic cancer
by: Marco Massani, et al.
Published: (2023-01-01) -
Prognostic value of neoadjuvant therapy for resectable and borderline resectable pancreatic cancer: A meta-analysis of randomized controlled trials.
by: Shangtong Liu, et al.
Published: (2023-01-01) -
Multicenter randomized controlled trial of neoadjuvant chemoradiotherapy alone or in combination with pembrolizumab in patients with resectable or borderline resectable pancreatic adenocarcinoma
by: Craig L Slingluff, et al.
Published: (2023-12-01) -
The Right Treatment Strategy for the Right Patient: A Biomarker-Driven Approach to Neoadjuvant vs. Surgery-First Management of Resectable and Borderline Resectable Pancreatic Cancer
by: Christopher B. Nahm, et al.
Published: (2022-07-01)